This preprint evaluated the protective effect of the trivalent influenza vaccine among Brazilian patients hospitalised for severe acute respiratory infection (SARI) during 2023–2025. The author emphasises that, despite increased influenza burden in 2025, prior effectiveness assessments had not covered the end-of-winter period. The report is a medRxiv preprint and has not been peer reviewed; it therefore should not be used to guide clinical practice without further validation.
Secondary surveillance data covering January 2003 through October 2025 were retrieved and analysed. The study used the number of trivalent influenza vaccine doses received within a calendar year as the primary exposure variable. Outcomes evaluated were in-hospital mortality, total hospital length of stay, use of the intensive care unit (ICU), and ICU length of stay. Analyses were performed using Poisson regression to estimate relative reductions in outcomes by vaccine dose category.
The dataset referenced for public access was the OpenDataSUS SRAG collection (dataset link provided in the source). The abstract does not report additional analytic details such as covariates included in regression models, sample sizes, or measures of statistical uncertainty (for example, confidence intervals or p-values); those details were not provided in the source text.
The exposure categories were unvaccinated, one vaccine dose in the calendar year, and two vaccine doses in the calendar year. The primary clinical endpoints reported in the abstract were:
Poisson regression was the modelling approach used to estimate relative changes in these outcomes associated with vaccine dose count.
Vaccine uptake among patients hospitalised with SARI declined across the study window reported in the abstract: approximately 70% uptake in 2023 fell to roughly 40–50% in both 2024 and 2025.
Compared with unvaccinated patients, receiving a single influenza vaccine dose in the same calendar year was associated with modest reductions in measured outcomes, estimated at about 10–13%.
Receiving two influenza vaccine doses within the calendar year was associated with larger reductions in adverse hospital outcomes. Specifically, the abstract reports:
The abstract states that two doses were “moderately effective” in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients. The source does not provide raw counts, absolute risk reductions, subgroup breakdowns, time-to-event analyses, or statistical uncertainty measures in the provided text.
From the surveillance-based analysis, a dose–response pattern is suggested: higher vaccine exposure (two doses in a calendar year) was associated with greater relative reductions in mortality and ICU-related outcomes than a single dose. The author highlights a policy implication: adding 50–59-year-olds to priority vaccination groups could materially reduce influenza-related adverse outcomes in hospitalised SARI patients.
These findings are presented as associations from observational surveillance data analysed with Poisson regression. Causal inference is limited by the observational design and by the absence of detailed adjustment information in the abstract.
The provided source material is an abstract of a medRxiv preprint; it lacks several methodological and result-level details that are important for critical appraisal. Specifically, the abstract does not report sample sizes, demographic or clinical covariates, confidence intervals or p-values, diagnostic checks for model fit, or methods for handling missing data. The author notes the study used national surveillance data, but the abstract does not describe case ascertainment criteria, laboratory confirmation rates for influenza, or potential sources of bias such as differential healthcare access or confounding by indication. These limitations should be addressed in the full text and verified through peer review.
In this preprint analysis of Brazilian surveillance data, receipt of two trivalent influenza vaccine doses in a calendar year was associated with substantial relative reductions in in-hospital mortality, ICU admissions, and ICU length of stay among patients hospitalised with SARI; a single dose showed more modest reductions. The author suggests expanding priority vaccination to include 50–59-year-olds as a potential public health measure.
Because the paper is a preprint that has not undergone peer review and the abstract omits detailed methods and statistical estimates, these results should be interpreted cautiously and validated with the full report or subsequent peer-reviewed publication.
The data source cited is OpenDataSUS (SRAG dataset for 2021–2024). The preprint declares funding from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasil (grant number provided in the source). The authors declared no competing interests in the submission.